Table 1.
Summary of published studies and the characteristic of patients.
| Author | Country | Year | Study design | Article type | No. of patients | Median age (years) | Gender (male) | Depth of invasion (%) SM1 |
Tumor size (mm) | Follow-up (months) | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiu | China | 2012 | Retrospective | Full text | ESD 74/surgery 40 | ESD66.3 (14–88)/surgery 67.0 (33–84) | ESD 66.2%/surgery 57.5 | ESD 10.8%/surgery 52.5% | ESD 18.5 (8–40)/surgery 24.7 (10–40) | ESD 27.0 (range 1–65)/surgery 77.6 (range 1–180) | 7 |
| Cho | Korea | 2016 | Retrospective | Full text | ESD 88/surgery 88 | ESD (61.8 ± 9.8)/surgery (61.3 ± 9.8) | ESD 71.6%/surgery 70.5 | ESD 17.0%/surgery 20.5% | ESD 21.8 ± 12.1/surgery 21.4 ± 10.1 | ESD 77 (range 18–107)/surgery 78 (range 1–113) | 7 |
| Choi | Korea | 2015 | Cross-sectional | Full text | ESD 137 /surgery 188 | ESD 67.2 (SD 9.9)/surgery 61.4 (SD 11.5) | ESD 75.2%/surgery 67.0% | ESD 4.4%/surgery 15.4% | N/A | N/A | N/A |
| Chung | Korea | 2014 | Retrospective | Full text | ESD 76/surgery 149 | ESD (60.1 ± 13.2)/surgery (56.7 ± 12.8) | ESD 75.2%/surgery 67.0% | N/A | ESD ≤ 10 (18.4%), >10 ≤ 20 (57.9%), >20 ≤ 40 (19.7%), >4 (3.9%)/surgery ≤ 10 (27.5%), >10 ≤ 20 (72.5%), >2 ≤ 40 (0%), >4 (0%) | ESD 41.7 ± 22.6 (SD)/surgery 42.8 ± 17.3 (SD) | 7 |
| Kim | Korea | 2014 | Retrospective | Full text | ESD 142/surgery 71 | ESD (62.0 ± 10.3)/surgery (56.7 ± 12.0) | ESD 66.2%/surgery 81.7% | ESD 4.9%/surgery 12.7% | ESD ≤ 10 (16.9%), ≤20 (72.7%), ≤30 (21.1%), >30 (12.7%)/surgery ≤ 10 (15.5%), ≤20 (54.9%), ≤30 (14.1%), >30 (15.5%) | ESD 76.7 ± 16.5 (SD)/surgery 65.5 ± 16.5 (SD) | 7 |
| Najmeh | Canada | 2016 | Retrospective | Full text | ESD 30/surgery 37 | ESD74 (40–86)/surgery 75 (34–86) | ESD 77%/surgery 65% | N/A | ESD 1.8 (0–5)/surgery 2.8 (0–9) | ESD 74 (range 40–86)/surgery 75 (range 34–86) | 7 |
| Park | Korea | 2014 | Retrospective | Full text | ESD 132/surgery 132 | ESD (73.9 ± 3.5)/surgery (74.4 ± 3.7) | ESD 73.5%/surgery 66.7% | ESD 6.8%/surgery 6.8% | ESD < 10 (39.4%), 10–20 (40.9%), 20–30 (13.6%), >30 (6.1%)/surgery < 10 (34.1%), 10–20 (43.2%), 20–30 (13.6%), >30 (9.1%) | ESD 17.6 (range 9.9–25.7)/surgery 24.2 (range 12.5–36.7) | 7 |
| Ryu | Korea | 2016 | Retrospective | Full text | ESD 81/surgery 144 | ESD (63.65 ± 8.57)/surgery (61.37 ± 9.50) | ESD 72.8%/surgery 81.9% | N/A | ESD 19.32 ± 11.31/surgery 20.55 ± 10.68 | ESD 78.12 ± 9.72 (SD)/surgery 80.56 ± 8.92 (SD) | 7 |
| Shin | Korea | 2016 | Retrospective | Full text | ESD 175/surgery 100 | ESD (61.7 ± 8.7)/surgery (60.5 ± 9.7) | ESD 73.7%/surgery 73% | ESD 1.7%/surgery 1.0% | ESD major axis 12.4 ± 6.9 and minor axis 8.8 ± 4.9/surgery major axis 15.2 ± 8.7 and minor axis 12.0 ± 6.6 | ESD 56 (range 45–58)/surgery 53 (range 44–60) | 7 |
| Soh | Korea | 2016 | Retrospective | Full text | ESD 55/surgery 27 | ESD (52 (42–57))/surgery (53 (46–63)) | ESD 38.2%/surgery 55.6% | N/A | ESD 15 (10–20)/surgery 27 (20–35) | ESD 30 (range 15–49)/surgery 20 (range 9–37) | 7 |
| Song | China | 2015 | Retrospective | Full text | ESD 29/surgery 59 | ESD (65.3 ± 7.5)/surgery (45.8 ± 6.7) | N/A | ESD 7.0%/surgery 0.3% | ESD 27 ± 19/surgery 35 ± 16 | ESD 26.9 ± 8.5 (SD)/surgery 22.3 ± 9.4 (SD) | 7 |
| Kim | Korea | 2015 | Retrospective | Full text | ESD 82/surgery 112 | N/A | N/A | N/A | N/A | 24 | 7 |
| Fukunaga | Japan | 2016 | Retrospective | Full text | ESD 74/surgery 74 | ESD (67.3 ± 8.8)/surgery (67.1 ± 7.5) | ESD 23%/surgery 21.6% | ESD 21.6%/surgery 18.9% | ESD 23.1 ± 10.1/surgery 24.7 ± 11.4 | ESD 43.5 (IQR 26.3–76.0)/surgery 62.9 (IQR 36.5–91.7) | 7 |
ESD: endoscopic submucosal dissection; SM1: tumor infiltration into the submucosal layer/500 μm from the muscularis mucosae; SD: standard deviations; IQR: interquartile range; N/A: not available.